PCSK9 and diabetes mellitus: The findings suggest a potential benefit of PCSK9 inhibition in the early phase of ACS, especially for patients with DM plus high PCSK9 levels, by a twofold mechanism on both lipid lowering and inflammation/platelet pathways.